Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Crossbow Therapeutics $77 million Series B for TCR-mimetics

Lucid Diligence Brief: Crossbow Therapeutics $77 million Series B for…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Samsung Bioepis and G2GBIO long-acting semaglutide collaboration

Lucid Diligence Brief: Samsung Bioepis and G2GBIO long-acting semaglutide…


Artificial_Intelligence

AI in Healthcare and Digital Health Today—March 16, 2026

 This week’s AI in Healthcare and Digital Health update highlights…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Universal Health Services acquires Talkspace for $835 million

Lucid Diligence Brief: Universal Health Services acquires Talkspace for $835…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: PRISM BioLab × Receptor.AI collaboration

Lucid Diligence Brief: PRISM BioLab × Receptor.AI collaboration Professional…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Enodia Therapeutics Kezar Sec61 deal

Lucid Diligence Brief: Enodia Therapeutics Kezar Sec61 deal Professional…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Agilent acquires Biocare Medical for $950 million

Lucid Diligence Brief: Agilent acquires Biocare Medical for $950 million…


Artificial_Intelligence

AI in Healthcare and Digital Health Video Recap—March 11, 2026

This biweekly AI in Healthcare and Digital Health video recap highlights safety…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Eli Lilly $500 million South Korea biopharma pledge

Lucid Diligence Brief: Eli Lilly $500 million South Korea biopharma pledge…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: kyron.bio x Servier strategic partnership

Lucid Diligence Brief: kyron.bio x Servier strategic partnership Professional…


Privacy Preference Center